Cargando…

Once-Daily OROS Hydromorphone for Management of Cancer Pain: an Open-Label, Multi-Center, Non-Interventional Study

Extended-release osmotic extended-release oral delivery system (OROS) hydromorphone is a strong synthetic opioid designed to maintain a constant blood concentration by once daily dosing. The objective of this observational study was to investigate the clinical usefulness of OROS hydromorphone in pat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Park, Cheol Kyu, Kang, Hyun-Wook, Oh, In-Jae, Kim, Young-Chul, Kim, Yeo-Kyeoung, Na, Kook-Joo, Ahn, Sung-Ja, Kim, Tae Ok, Choi, Young Jin, Song, Geun Am, Lee, Min Ki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Academy of Medical Sciences 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5102854/ https://www.ncbi.nlm.nih.gov/pubmed/27822929 http://dx.doi.org/10.3346/jkms.2016.31.12.1914

Ejemplares similares

Repeat-dose steady-state pharmacokinetic evaluation of once-daily hydromorphone extended-release (OROS(®) hydromorphone ER) in patients with chronic pain
por: Vandenbossche, Joris, et al.
Publicado: (2012)

Once-daily OROS® hydromorphone for the management of chronic nonmalignant pain: a dose-conversion and titration study
por: Wallace, M, et al.
Publicado: (2007)

An open-label, 1-year extension study of the long-term safety and efficacy of once-daily OROS(® )hydromorphone in patients with chronic cancer pain
por: Hanna, Magdi, et al.
Publicado: (2009)

Complementary pharmacokinetic measures to further define the profile of once-daily OROS hydromorphone ER during single-dose and steady-state dosing
por: Devarakonda, Krishna, et al.
Publicado: (2013)

Clinical Usefulness of Hydromorphone-OROS in Improving Sleep Disturbances in Korean Cancer Patients: A Multicenter, Prospective, Open-Label Study
por: Shin, Seong Hoon, et al.
Publicado: (2014)

Effectiveness and gastrointestinal tolerability during conversion and titration with once-daily OROS® hydromorphone extended release in opioid-tolerant patients with chronic low back pain
por: Hale, Martin E, et al.
Publicado: (2013)

A new extended release formulation (OROS(®)) of hydromorphone in the management of pain
por: Weinstein, Sharon M
Publicado: (2009)

Clinical Characteristics of Patients Responding to Once-Daily Basal Insulin Therapy in Korean Subjects with Type 2 Diabetes
por: Song, Sun Ok, et al.
Publicado: (2015)

The protective effect of hydromorphone to ischemia in rat glial cells
por: Kim, Young Sung, et al.
Publicado: (2016)

Pharmacokinetic profile of a 24-hour controlled-release OROS(® )formulation of hydromorphone in the presence and absence of food
por: Sathyan, Gayatri, et al.
Publicado: (2007)

A randomized, double-blind comparison of OROS(® )hydromorphone and controlled-release morphine for the control of chronic cancer pain
por: Hanna, Magdi, et al.
Publicado: (2008)

Comparison of once-daily versus twice-daily combination of Ropinirole prolonged release in Parkinson’s disease
por: Yun, Ji Young, et al.
Publicado: (2013)

A prospective multicentre study to evaluate the efficacy and tolerability of osmotic release oral system (OROS(®)) hydromorphone in opioid-naive cancer patients: Results of the Korean South West Oncology Group study
por: Song, Eun-Kee, et al.
Publicado: (2015)

Efficacy and safety of a switch from twice-daily tacrolimus to once-daily generic tacrolimus in stable liver transplant patients
por: Kim, Jong Man, et al.
Publicado: (2021)

Twice-Daily versus Once-Daily Pramipexole Extended Release Dosage Regimens in Parkinson's Disease
por: Yun, Ji Young, et al.
Publicado: (2017)

Effect of ketamine on intravenous patient-controlled analgesia using hydromorphone and ketorolac after the Nuss surgery in pediatric patients
por: Min, Too Jae, et al.
Publicado: (2012)

Rivaroxaban Once-Daily vs. Dose-Adjusted Vitamin K Antagonist on Biomarkers in Acute Decompensated Heart Failure and Atrial Fibrillation (ROAD HF-AF): Rationale and Design of an Investigator-Initiated Multicenter Randomized Prospective Open-Labeled Pilot Clinical Study
por: Cho, Iksung, et al.
Publicado: (2022)

Switching from Methylphenidate-Immediate Release (MPH-IR) to Methylphenidate-OROS (OROS-MPH): A Multi-center, Open-label Study in Korea
por: Kim, Bung-Nyun, et al.
Publicado: (2011)

Acute suicidal ideations responsive to hydromorphone
por: Rotchford, James Kimber
Publicado: (2019)

Unintentional administration of intra‐articular hydromorphone
por: Doyle, Stephen, et al.
Publicado: (2021)

Analgosedation: The Use of Fentanyl Compared to Hydromorphone
por: Choi, Hahnl, et al.
Publicado: (2021)

Once-daily dosing of gentamicin.
por: Soper, D E
Publicado: (1998)

Mycobacteremia from Crushed Hydromorphone Tablet Injection
por: Banno, Joseph M, et al.
Publicado: (2017)

Hydromorphone attenuates intercellular adhesion molecule-1 expressions induced by lipopolysaccharide on HCT-116 human colon cancer cells
por: Lee, Jae Jin, et al.
Publicado: (2014)

The Effect of Orally Administered Ranitidine and Once‐Daily or Twice‐Daily Orally Administered Omeprazole on Intragastric pH in Cats
por: Šutalo, S., et al.
Publicado: (2015)

ONCE DAILY RISPERIDONE IN TREATMENT OF SCHIZOPHRENIA
por: Agarwal, Vivek, et al.
Publicado: (2001)

A Randomized, Open-Label Comparison of Once-Weekly Insulin Icodec Titration Strategies Versus Once-Daily Insulin Glargine U100
por: Lingvay, Ildiko, et al.
Publicado: (2021)

Tendrás oro y oro /
por: Sender, Rafael
Publicado: (1985)

Two orthorhombic polymorphs of hydromorphone
por: Mazurek, Jaroslaw, et al.
Publicado: (2016)

Hydromorphone/lorazepam/morphine overdose: Coma: case report
Publicado: (2019)

Comparison of Once-Daily Bromfenac 0.07% Versus Once-Daily Nepafenac 0.3% in Patients Undergoing Phacoemulsification
por: Toyos, Melissa M.
Publicado: (2019)

Vitiligo-like depigmentation after pembrolizumab treatment in patients with non-small cell lung cancer: a case report
por: Yun, Sook Jung, et al.
Publicado: (2020)

Recommendation for response to the COVID-19 pandemic: Korean context of “distancing in daily life,” considering vulnerable population
por: Kim, Ja Young, et al.
Publicado: (2020)

Benefits of once-daily therapies in the treatment of hypertension
por: Flack, John M, et al.
Publicado: (2011)

ONCE DAILY LITHIUM IN THE PROPHYLAXIS OF MOOD DISORDERS
por: Mohan, Rajesh, et al.
Publicado: (1996)

Safety and Efficacy of Once-Daily Prolonged-Release Tacrolimus in Living Donor Liver Transplantation: An Open-Label, Prospective, Single-Arm, Phase 4 Study
por: Lee, Eung Chang, et al.
Publicado: (2018)

High-dose intravenous hydromorphone for patients who use opioids in the hospital setting: time to reduce the barriers
por: Labonté, Laura E., et al.
Publicado: (2021)

Assessment of setup uncertainties for various tumor sites when using daily CBCT for more than 2200 VMAT treatments
por: Oh, Young‐Kee, et al.
Publicado: (2014)

Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin
por: Kapitza, C, et al.
Publicado: (2013)

Safety and Efficacy of Conversion from Twice-Daily Tacrolimus to Once-Daily Tacrolimus One Month after Transplantation: Randomized Controlled Trial in Adult Renal Transplantation
por: Oh, Chang-Kwon, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_4unrkjjjgtf716m0vqgp4ht3ii